Scarica l'app Stockscreener
10.22
10.85%
1.00
Dopo l'orario di chiusura:
10.02
-0.20
-1.96%
Precedente Chiudi:
$9.22
Aprire:
$9.35
Volume 24 ore:
1.46M
Relative Volume:
1.79
Capitalizzazione di mercato:
$527.53M
Reddito:
$170.44M
Utile/perdita netta:
$-193.88M
Rapporto P/E:
-2.7224
EPS:
-3.7541
Flusso di cassa netto:
$-126.38M
1 W Prestazione:
+21.67%
1M Prestazione:
+16.14%
6M Prestazione:
-8.50%
1 anno Prestazione:
+29.04%
Intervallo 1D:
$9.295
$10.40
Intervallo di 1 settimana:
$8.55
$10.40
Portata 52W:
$6.89
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
10.22 | 475.91M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-02-11 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-07 | Ripresa | Raymond James | Outperform |
| 2024-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-06-07 | Iniziato | Goldman | Buy |
| 2024-03-11 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Ripresa | Raymond James | Outperform |
| 2023-11-01 | Iniziato | Stifel | Buy |
| 2023-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Wedbush | Neutral |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-14 | Ripresa | Raymond James | Outperform |
| 2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
| 2018-11-08 | Reiterato | BofA/Merrill | Neutral |
| 2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
| 2018-05-09 | Reiterato | Barclays | Overweight |
| 2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Iniziato | Mizuho | Neutral |
| 2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy - The AI Journal
Duchenne gene therapy trial results are due in REGENXBIO webcast - Stock Titan
Behavioral Patterns of RGNX and Institutional Flows - Stock Traders Daily
RGNX Stock Price, Quote & Chart | REGENXBIO INC (NASDAQ:RGNX) - ChartMill
Morgan Stanley cuts Regenxbio stock price target on model updates - Investing.com
MSN Money - MSN
Duchenne Muscular Dystrophy Pipeline 2026: FDA Updates, - openPR.com
Duchenne Muscular Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Vertex Pharma, Bioleaders Corp., Wave Life Sciences, REGENXBIO - Barchart.com
Diabetic Retinopathy Pipeline Set for Transformational Breakthroughs by 2026 with 55+ Therapies expanding Clinical Innovation from Kodiak Sciences, Regenxbio, Adverum Biotechnologies | DelveInsight - Barchart
Diabetic Retinopathy Pipeline Set for Transformational - openPR.com
Regenxbio files $300M mixed shelf offering - MSN
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Federal Circuit Rejects Biotech Company’s Rehearing Bid For DNA Patent Claims - Mealey's
Regenxbio's DB-OTO Gene Therapy Approved for Genetic Hearing Los - GuruFocus
Sarepta Loses Bid to Rehear Regenxbio DNA Patent Case Decision - Bloomberg Law News
(RGNX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
RGNX (REGENXBIO Inc.) reports wider than expected Q4 2025 loss while shares climb on positive investor sentiment.Market Hype Signals - Xã Thanh Hà
Full Fed. Circ. Passes On Sarepta's Patent Rehearing Bid - Law360
REGENXBIO credits administrative team for ongoing operational success - Traders Union
REGENXBIO (NASDAQ:RGNX) Shares Pass Below 200-Day Moving AverageShould You Sell? - MarketBeat
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against REGENXBIO Inc. (RGNX), Franklin BSP Realty Trust, Inc. (FBRT), and Aquestive Therapeutics, Inc. (AQST) Announced by Holzer & Holzer, LLC - WFXG
DNA Patent Eligibility Under Spotlight in Sarepta’s En Banc Bid - Bloomberg Law News
REGENXBIO prioritizes patient access by strengthening commercial leadership - Traders Union
Lifshitz Law Firm Investigating PayPal, Enphase Energy, and REGENXBIO - National Today
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of REGENXBIO Inc. to Contact the Firm Today! - ACCESS Newswire
RGNX DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts REGENXBIO Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
REGENXBIO Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
[ARS] REGENXBIO Inc. SEC Filing - Stock Titan
REGENXBIO (RGNX) 2026 proxy details director votes, auditor, and stock option exchanges - Stock Titan
RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REG - GuruFocus
User - The Chronicle-Journal
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AMC Entertainment Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMC; APE - GlobeNewswire Inc.
REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Eastern Progress
RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - The Joplin Globe
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026 - 巴士的報
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - GlobeNewswire
RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - PR Newswire
REGENXBIO DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class ActionRGNX - ACCESS Newswire
Levi & Korsinsky, LLP: RGNX Disclosure Timeline Reveals Pattern of Alleged Investor Harm - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - ChartMill
Rosen Law Firm Encourages REGENXBIO Investors to Secure Counsel Before Deadline - National Today
REGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages REGENXBIO, Inc. Investors with ... - Bluefield Daily Telegraph
REGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FIRM, - GlobeNewswire
How (RGNX) Movements Inform Risk Allocation Models - Stock Traders Daily
REGENXBIO DEADLINE: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class ActionRGNX - ACCESS Newswire
REGENXBIO DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class ActionRGNX - TMX Newsfile
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of REGENXBIO Inc. to Contact the Firm Today! - ACCESS Newswire
Portfolio Shifts: How is REGENXBIO Inc managing supply chain issues2026 Sentiment & High Conviction Investment Ideas - baoquankhu1.vn
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):